Highlights

Revenue growth and royalty streams continue to support cash-rich biotech platforms.
Regulatory approvals and commercial launches are creating near-term revenue inflection points.
Strategic corporate moves, including demergers and U.S. expansion, redefine operational focus.

Australia's biotechnology sector continues to evolve, with several companies marking significant milestones in their commercial and clinical journeys. Here's an overview of key ASX-listed biotech companies as of September 2025:

Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals reported a 63% year-on-year revenue increase in H1 2025, reaching AUD 390.4m. This growth was primarily driven by Illuccix®, a PSMA-targeted imaging agent, and the acquisition of RLS Radiopharmacies, which expanded its distribution network. The company reaffirmed its FY 2025 revenue guidance of US$770–800m, reflecting continued demand for Illuccix® and the integration of RLS.

Neuren Pharmaceuticals (ASX:NEU)

Neuren Pharmaceuticals reported a 14% increase in net sales of DAYBUE™ (trofinetide) in Q2 2025, totaling US$96.1m. This growth contributed to a 14% rise in royalties, amounting to AUD 28.3m. The company is also advancing NNZ-2591, a drug candidate in development for multiple neurodevelopmental disorders, with positive Phase 2 results prompting plans for Phase 3 trials.

Clinuvel Pharmaceuticals (ASX:CUV)

Clinuvel Pharmaceuticals achieved a 10% increase in revenue for FY 2025, totaling AUD 105.3m, driven by sales of SCENESSE® (afamelanotide) for the treatment of erythropoietic protoporphyria (EPP). The company also reported a net profit of AUD 36.2m and a cash balance of AUD 224m. Clinuvel is progressing its Phase III vitiligo program, aiming to expand its product indications.

CSL Limited (ASX:CSL)

CSL Limited reported a 17% increase in net profit after tax (NPAT) for FY 2025, totaling US$3.0bn. The company announced plans to demerge its Seqirus influenza vaccine unit into a standalone ASX-listed entity by the end of FY 2026. This strategic move aims to streamline operations and focus on core business areas.

Mesoblast (ASX:MSB)

Mesoblast's Ryoncil® (remestemcel-L-rknd) received FDA approval in December 2024 for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in pediatric patients. This marked the first approval of a mesenchymal stromal cell therapy in the U.S. The company is now focusing on commercializing Ryoncil® and exploring additional indications.

Orthocell (ASX:OCC)

Orthocell received U.S. FDA 510(k) clearance for Remplir™, a nerve-repair collagen wrap, in April 2025. The company has commenced distribution and logged its first U.S. use, targeting the approximately US$1.6bn nerve-repair market. Orthocell is focusing on building U.S. surgeon adoption and distributor coverage.

Imugene (ASX:IMU)

Imugene continues to advance its immuno-oncology pipeline, including azer-cel (allo CAR-T) and CF33 oncolytic virus. In August 2025, the company reported that 11 out of 14 patients treated with azer-cel achieved an overall response rate of 79%. Imugene is also exploring combination therapies and expanding its clinical trials.

September 2025 highlights a diverse mix of ASX-listed biotech companies advancing commercial revenues, regulatory milestones, and clinical pipelines. However, sector dynamics can be influenced by macro factors such as AUD movements, reimbursement policies, and hospital budget cycles.